Designation of Selexipag as an Orphan Drug - Actelion Pharmaceuticals Australia Pty Ltd

Overview

The Therapeutic Goods Act 1989, enacted by the Parliament of Australia, aims to regulate therapeutic goods, including medicines, medical devices, and blood and tissues, to ensure they are of acceptable quality, safety, and efficacy. This Act was introduced to address the need for a comprehensive regulatory framework to protect public health by controlling the supply and distribution of therapeutic goods. The Act provides the Therapeutic Goods Administration with the authority to oversee the manufacture, importation, and distribution of these goods. Specifically, the designation of selexipag as an orphan drug under the Act highlights the policy objective of encouraging the development and availability of treatments for rare diseases, thereby addressing a gap in therapeutic options for conditions like pulmonary arterial hypertension.

Scope and Application

The Therapeutic Goods Act 1989 applies to the designation of certain therapeutic goods, including drugs, within the Commonwealth of Australia. This Act is administered by the Therapeutic Goods Administration, a department within the Commonwealth Government. In the context of the gazette C2014G01630, the Act and its associated regulations empower the designation of specific drugs, such as selexipag, as orphan drugs for particular medical conditions. Selexipag has been designated as an orphan drug for the treatment of pulmonary arterial hypertension, indicating that it is intended for a small patient population with a rare disease, thus warranting special consideration and support for research and development. The sponsor of this drug, Actelion Pharmaceuticals Australia Pty Ltd, is subject to the provisions of the Therapeutic Goods Act and its regulations, which govern the approval, listing, and monitoring of therapeutic goods in Australia. The designation of selexipag under the orphan drug framework is intended to facilitate the availability of this treatment option for patients suffering from pulmonary arterial hypertension.

Key Provisions

The main operative sections of the Therapeutic Goods Act 1989, as applied in the designation of selexipag as an orphan drug, are primarily found within the Therapeutic Goods Regulations 1990. Section 16J of the Regulations allows for the designation of certain drugs as orphan drugs, which are intended for the treatment of rare medical conditions. Under subregulation 16J(2), the Delegate of the Secretary is authorised to designate a therapeutic good as an orphan drug if it meets the criteria set forth in the Regulations. In this instance, selexipag has been designated as an orphan drug for the treatment of pulmonary arterial hypertension, as detailed in the official gazette issued on 25 September 2014 by Dr Anthony Gill, the Delegate of the Secretary. The Therapeutic Goods Act 1989 imposes several obligations and requirements on the parties involved in the governance of therapeutic goods. For entities like Actelion Pharmaceuticals Australia Pty Ltd, the sponsor of selexipag, there are obligations to ensure that the therapeutic good meets the necessary standards for safety, efficacy, and quality. This includes providing sufficient evidence and data to support the orphan drug designation. The sponsor must also ensure that the product is manufactured and distributed in compliance with the Act and Regulations, including adherence to labelling and advertising requirements. Furthermore, the sponsor is responsible for reporting any adverse events associated with the use of the drug and maintaining records that can be accessed for regulatory purposes. Failure to comply with the provisions of the Therapeutic Goods Act 1989 and the Therapeutic Goods Regulations 1990 can result in a range of civil and criminal consequences. Under the Act, breaches can lead to actions such as product recalls, fines, and imprisonment. For instance, if a sponsor fails to report adverse events or provides misleading information about the therapeutic good, they may face significant penalties. The maximum penalties for serious offences can include substantial fines for corporations and imprisonment for individuals. Additionally, the Act provides for the issuance of infringement notices for less serious breaches, which can result in fines up to a certain monetary limit. These provisions are designed to ensure that therapeutic goods on the market are safe, effective, and of high quality, thereby protecting public health.